N/A
Manufactured by Mylan Institutional LLC
13,905 FDA adverse event reports analyzed
Last updated: 2026-04-14
FONDAPARINUX SODIUM is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Mylan Institutional LLC. The most commonly reported adverse reactions for FONDAPARINUX SODIUM include ANAEMIA, HAEMATOMA, PULMONARY EMBOLISM, OFF LABEL USE, HAEMORRHAGE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for FONDAPARINUX SODIUM.
Out of 7,978 classified reports for FONDAPARINUX SODIUM:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 13,905 FDA FAERS reports that mention FONDAPARINUX SODIUM. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include ANAEMIA, HAEMATOMA, PULMONARY EMBOLISM, OFF LABEL USE, HAEMORRHAGE, HAEMOGLOBIN DECREASED. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Mylan Institutional LLC in connection with FONDAPARINUX SODIUM. Always verify the specific product and NDC with your pharmacist.